Skip to main content
Signal8
Launch Terminal

MYRIAD GENETICS INC (MYGN)

Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women’s health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. In addition, the company offers Prolaris Prostate Cancer Prognostic test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor Molecular Profile test, a genomic profiling test; Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus; Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek Early Gender DNA test, a non-invasive blood test that predicts the gender of a fetus; FirstGene; and GeneSight Psychotropic Mental Health Medication test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit/hyperactivity disorder, and other mental health conditions. It has a license collaboration with Illumina, Inc.; University of Texas M.D. Anderson Cancer Center; Mayo Foundation for Medical Education and Research; Children’s Medical Center in Boston; Institut Curie and INSERM; and Eurobio Scientific SA. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.

Sector: In Vitro & In Vivo Diagnostic Substances

Industry: Medical - Diagnostics & Research

Myriad Genetics, Inc. logo

Myriad Genetics, Inc.

NASDAQ:MYGNHealthcare
-4.80%$6.35
AH$6.35+0.00%vs close
Mkt Cap$607.38M
Float92.05M
O/S95.65M
Vol
$ Vol
RVOL
Inst Own92.8%
SI10.1%
Earnings
Dilution
Myriad Genetics, Inc. logoNASDAQ:MYGN$6.35-4.80%
Phase Distribution
18 trials as collaborator·5 active·12 completed
Phase 12
Phase 1/21
Phase 24
Phase 35
Phase 41
Not applicable5
(no lead-sponsored trials found)
Status Overview
Recruiting2
Active, not recruiting3
Completed12
Stopped1

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Status
Phase
  • Phase 4
    Active, not recruiting

    Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 Mutations

    Collaborator · Lead: AstraZeneca

    olaparib, enzalutamide

    Metastatic Castration-resistant Prostate Cancer

    Enrollment
    43
    Start
    Jul 2022
    Primary Completion
    Oct 2024
    Completion
    Dec 2026est.
    NCT05457257
  • Phase 3
    Completed

    A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer

    Collaborator · Lead: Tesaro, Inc.

    Active comparator: Niraparib, placebo

    Ovarian Neoplasms, Platinum Sensitive Ovarian Cancer

    Enrollment
    596
    Start
    Jun 2013
    Primary Completion
    Apr 2016
    Completion
    Dec 2021
    NCT01847274
  • Phase 3
    Completed

    Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous or Endometrioid Ovarian Cancer (ARIEL3)

    Collaborator · Lead: pharmaand GmbH

    Rucaparib, Placebo

    Ovarian Cancer, Fallopian Tube Cancer +1

    Enrollment
    564
    Start
    Apr 2014
    Primary Completion
    Apr 2017
    Completion
    Jul 2022
    NCT01968213
  • Phase 3
    Active, not recruiting

    A Study of Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy

    Collaborator · Lead: Tesaro, Inc.

    Niraparib, Placebo

    Ovarian Neoplasms

    Enrollment
    733
    Start
    Jul 2016
    Primary Completion
    May 2019
    Completion
    May 2026est.
    NCT02655016
  • Phase 3
    Completed

    Study of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study)

    Collaborator · Lead: AstraZeneca

    olaparib, enzalutamide

    Metastatic Castration-resistant Prostate Cancer

    Enrollment
    387
    Start
    Feb 2017
    Primary Completion
    Jun 2019
    Completion
    Feb 2023
    NCT02987543
  • Phase 3
    Completed

    Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed Non gBRCAm Ovarian Cancer Patients

    Collaborator · Lead: AstraZeneca

    Olaparib

    Non-Germline BRCA Mutated Ovarian Cancer

    Enrollment
    279
    Start
    Jan 2018
    Primary Completion
    Oct 2020
    Completion
    Mar 2022
    NCT03402841
  • Phase 2
    Completed

    A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2)

    Collaborator · Lead: pharmaand GmbH

    Oral rucaparib

    Ovarian Cancer, Epithelial Ovarian Cancer +2

    Enrollment
    491
    Start
    Oct 2013
    Primary Completion
    Nov 2019
    Completion
    Sep 2021
    NCT01891344
  • Phase 2
    Completed

    Cisplatin vs Paclitaxel for Triple Negative Breast Cancer

    Collaborator · Lead: Dana-Farber Cancer Institute

    Cisplatin, Paclitaxel

    Triple Negative Breast Cancer

    Enrollment
    147
    Start
    Apr 2014
    Primary Completion
    Jan 2019
    Completion
    Aug 2020
    NCT01982448
  • Phase 2
    Completed

    A Study of Niraparib in Patients With Ovarian Cancer Who Have Received Three or Four Previous Chemotherapy Regimens

    Collaborator · Lead: Tesaro, Inc.

    Niraparib

    Ovarian Neoplasms, Ovarian Cancer

    Enrollment
    463
    Start
    Mar 2015
    Primary Completion
    Feb 2018
    Completion
    Aug 2021
    NCT02354586
  • Phase 2
    Active, not recruiting

    SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors

    Collaborator · Lead: Klus Pharma Inc.

    SKB264, Pembrolizumab

    Solid Tumor

    Enrollment
    240
    Start
    Jan 2023
    Primary Completion
    Nov 2027est.
    Completion
    Dec 2027est.
    NCT05642780
  • Phase 1/2
    Completed

    Niraparib Versus Niraparib-bevacizumab Combination in Women With Platinum-sensitive Epithelial Ovarian Cancer

    Collaborator · Lead: Nordic Society of Gynaecological Oncology - Clinical Trials Unit

    Niraparib, Bevacizumab

    Ovarian Cancer

    Enrollment
    108
    Start
    Feb 2015
    Primary Completion
    Nov 2018
    Completion
    Dec 2021
    NCT02354131
  • Phase 1
    Completed

    Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Participants With Locally Advanced or Metastatic Solid Tumors

    Collaborator · Lead: BeiGene

    Pamiparib, Temozolomide

    Locally Advanced or Metastatic Solid Tumors

    Enrollment
    139
    Start
    Jun 2017
    Primary Completion
    May 2023
    Completion
    May 2023
    NCT03150810
  • Phase 1
    Recruiting

    SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells

    Collaborator · Lead: General Oncology, Inc.

    Melphalan, BCNU

    Pancreatic Adenocarcinoma Metastatic, BRCA1 Mutation +18

    Enrollment
    24
    Start
    Jan 2021
    Primary Completion
    Dec 2028est.
    Completion
    Dec 2028est.
    NCT04150042
  • Not applicable
    Completed

    Prospective Study Assessing EndoPredict® Genomic Test Impact on Shared Decision of Adjuvant Chemotherapy in Patients With ER-positive, Her2-negative Early Breast Cancer

    Collaborator · Lead: UNICANCER

    EPClin genomic test

    Breast Cancer

    Enrollment
    203
    Start
    Sep 2016
    Primary Completion
    Sep 2017
    Completion
    Dec 2017
    NCT02773004
  • Observational
    Terminated

    Genetic Evaluation of Men (GEM)

    Collaborator · Lead: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University

    GEM Registry

    Prostate Cancer

    Enrollment
    595
    Start
    Oct 2014
    Primary Completion
    Jan 2019
    Completion
    May 2019
    NCT03076242
  • Observational
    Completed

    Impact of a Process Intervention on Screening and Testing Outcomes for Common Hereditary Cancer Syndromes

    Collaborator · Lead: Myriad Genetic Laboratories, Inc.

    Diagnostic Test

    Hereditary Cancer

    Enrollment
    145
    Start
    Feb 2017
    Primary Completion
    Jul 2017
    Completion
    Aug 2017
    NCT03081455
  • Not applicable
    Completed

    Genetic Testing for All Breast Cancer Patients (GET FACTS)

    Collaborator · Lead: Brigham and Women's Hospital

    Standard Genetic Counseling, Quantitative Genetic Counseling

    Breast Cancer, Invasive Breast Cancer +2

    Enrollment
    400
    Start
    Jan 2020
    Primary Completion
    Dec 2025
    Completion
    Jan 2026
    NCT04245176
  • Not applicable
    Recruiting

    Trial of Combined Obstetric Carrier Screening and Hereditary Cancer Screening

    Collaborator · Lead: Weill Medical College of Cornell University

    MyRisk Hereditary Cancer Test

    Hereditary Cancer Syndromes

    Enrollment
    550
    Start
    Sep 2025
    Primary Completion
    Jun 2027est.
    Completion
    Dec 2028est.
    NCT07052266
Search ClinicalTrials.gov for “Myriad Genetics”